PL
 |
EN
Ten serwis zostanie wyłączony 2025-02-11.
Nowa wersja platformy, zawierająca wyłącznie zasoby pełnotekstowe, jest już dostępna.
Przejdź na https://bibliotekanauki.pl

PL EN

Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników
Czasopismo

Acta Neurobiologiae Experimentalis

2020 | 80 | 3 |
Tytuł artykułu

Neuromyelitis optica spectrum disorder: an overview

Autorzy
Ramakrishnan P. , Nagarajan D.
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
Neuromyelitis optica also known as Devic’s syndrome is a rare autoimmune disorder that predominantly targets the optic nerves and the spinal cord. It is a debilitating disorder that damages a person’s health. Initially it was considered as a variant of multiple sclerosis (MS). But, in 2004, a water channel protein associated antibody was found to be responsible for the disease. This helped in distinguishing the disease from multiple sclerosis. Multiple molecular mechanisms like complement dependent cytotoxicity, antibody‑dependent cellular cytotoxicity etc. contribute to the disease. Certain environmental and genetic factors have been identified as risk factors of the disease. Initially, the disease was thought to affect only the optic nerves and the spinal cord. But certain regions of the brain have also been found to be attacked during the course of the disease. A small proportion of the patients have been found to be seronegative for the AQP4‑IgG. Recently, the term neuromyelitis optica spectrum disorder has been framed to include all the features of the disease. The disease remains incurable despite the availability of various treatment modalities. This review presents critical information obtained from prior studies regarding the disease and also raise several questions to understand the research gaps in this field.
Słowa kluczowe
Wydawca
-
Czasopismo
Acta Neurobiologiae Experimentalis
Rocznik
2020
Tom
80
Numer
3
Opis fizyczny
p.256-272,ref.
Twórcy
autor
Ramakrishnan P.
  • Radiation Biology Laboratory, School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India
autor
Nagarajan D.
  • Radiation Biology Laboratory, School of Chemical and Biotechnology, SASTRA University, Thanjavur, Tamil Nadu, India
Bibliografia
  • Aboul‑Enein F, Seifert‑Held T, Mader S, Kuenz B, Lutterotti A, Rauschka H, Rommer P, Leutmezer F, Vass K, Flamm‑Horak A, Stepansky R, Lang W, Fertl E, Schlager T, Heller T, Eggers C, Safoschnik G, Fuchs S, Kraus J, Assar H, Guggenberger S, Reisz M, Schnabl P, Komposch M, Simschitz P, Skrobal A, Moser A, Jeschow M, Stadlbauer D, Freimüller M, Guger M, Schmidegg S, Franta C, Weiser V, Koppi S, Niederkorn‑Duft M, Raber B, Schmeissner I, Jecel J, Tinchon A, Storch MK, Reindl  M, Berger T, Kristoferitsch W (2013) Neuromyelitis optica in Austria in 2011: to bridge the gap between neuroepidemiological research and practice in a study population of 8.4 million people. PLoS One 8: e79649.
  • Acchiote P (1907) Sur un cas de neuromyélite subaiguë ou maladie de Devic (in French). Bulletin officiels de la Société de neurologie de Paris 8–9: 273–275.
  • Algood H, Gallo‑Romero J, Wilson K, Peek Jr. R, Cover T (2007). Host response to helicobacter pylori infection before initiation of the adaptive immune response. FEMS Immunol Med Microbiol 51: 577–586.
  • Amiry‑Moghaddam  M, Xue R, Haug F, Neely JD, Bhardwaj A, Agre P, Adams M, Froehner S, Mori S, Ottersen O (2004) Alpha‑syntrophin deletion removes the perivascular but not endothelial pool of aquaporin‑4 at the blood‑brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia. FASEB J 18: 542–544.
  • Anaya J, Rojas‑Villarraga A, García‑Carrasco M (2012) The autoimmune tautology: from polyautoimmunity and familial autoimmunity to the auto‑ immune genes. Autoimmune Dis 2012: 297193.
  • Asgari N, Lillevang S, Skejoe H, Falah M, Stenager E, Kyvik K (2011) A population‑ based study of neuromyelitis optica in Caucasians. Neurology 76: 1589–1595.
  • Asgari N, Nielsen C, Stenager E, Kyvik KO, Lillevang S (2012) HLA, PTPN22 and PD‑ 1 associations as markers of autoimmunity in neuromyelitis optica. Mult Scler 18: 23–30.
  • Asgari N, Skejoe H, Lillevang S, Steenstrup, Stenager E, Kyvik K (2013) Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population‑based, descriptive study. BMC Neurol 13: 33.
  • Badri N, Teleb M, Syed S, Wardi M, Porres‑Aguilar M, Cruz‑Flores S (2016) Seronegative neuromyelitis optica: a  case report of a  Hispanic male. Case Rep Neurol 8: 102–107.
  • Barros P, Linhares U, Teixeira B, Kasahara T, Ferreira T, Alvarenga R, Hygino J, Silva‑ Filho R, Bittencourt V, Andrade R, Andrade A, Bento C (2013) High in vitro immune reactivity to Escherichia coli in neuromyeli‑ tis optica patients is correlated with both neurological disabilities and el‑ evated plasma lipopolysaccharide levels. Hum Immunol 74: 1080–1087.
  • Barros P, Cassano T, Hygino J, Ferreira T, Centurião N, Kasahara T, Andrade  R, Linhares U, Andrade A, Vasconcelos C, Alvarenga R, Marignier R, Bento C (2015) Prediction of disease severity in neuromy‑ elitis optica by the levels of IL‑6 produced during remission phase. Clin Exp Immunol 183: 480–489.
  • Bennett J, Lam C, Kalluri R, Saikali P, Bautista K, Dupree C, Glogowska M, Case D, Antel P, Owens P, Gilden D, Nessler S, Stadelmann C, Hemmer B (2009) Intrathecal pathogenic anti‑aquaporin‑4 antibodies in early neu‑ romyelitis optica. Ann Neurol 66: 617–629.
  • Bennett J, O’Connor K, Bar‑Or A, Zamvil S, Hemmer B, Tedder T, von Büdingen C, Stuve O, Yeaman M, Smith T, Stadelmann C (2015) B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2: e104.
  • Bennet J, Owens G (2017) Neuromyelitis optica: deciphering a complex im‑ mune‑mediated astrocytopathy. J Neuroophthalmol 37: 291–299.
  • Bradl  M, Kanamori Y, Nakashima I, Misu T, Fujihara K, Lassmann H, Sandkühler J (2014) Pain in neuromyelitis optica‑prevalence, pathogen‑ esis and therapy. Nat Rev Neurol 10: 529–536.
  • Bradl M, Lassmann H (2014) Experimental models of neuromyelitis optica. Brain Pathol 24: 74–82.
  • Briggs D, Naylor C, Smedley J, Lukoyanova N, Robertson S, Moss D, McClane  B, Basaka A (2011) Structure of the food‑poisoning Clostrid‑ ium perfringens enterotoxin reveals similarity to the aerolysin‑like pore‑forming toxins. J Mol Biol 413: 138–149.
  • Bruyn H, Sexton H, Brainerd H (1957) Mumps meningoencephalitis – A clinical review of 119 cases with one death. Calif Med 86: 153–160.
  • Bukhari W, Barnett M, Prain K, Broadley S (2012) Molecular pathogenesis of neuromyelitis optica. Int J Mol Sci 13: 12970–12993.
  • Bukhari  W, Prain K, Waters P, Woodhall  M, O’Gorman C, Clarke  L, Silvestrini  R, Bundell C, Abernethy D, Bhuta S, Blum S, Boggild  M, Boundy  K, Brew  B, Brown  M, Brownlee  W, Butzkueven H, Carroll  W, Chen C, Coulthard A, Dale R, Das C, Dear K, Fabis‑Pedrini M, Fulcher D, Gillis D, Hawke S, Heard  R, Henderson A, Heshmat S, Hodgkinson  S, Jimenez‑Sanchez  S, Killpatrick T, King J, Kneebone C, Kornberg A, Lechner‑Scott J, Lin  M, Lynch C, Macdonell R, Mason D, McCombe P, Pender M, Pereira J, Pollard J, Reddel S, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh  M, Wong R, Yiu E, Barnett  M, Kermode A, Marriott M, Parratt J, Slee M, Taylor B, Willoughby E, Wilson R, Vincent A, Broadley S (2017) Incidence and prevalence of NMOSD in Australia and New Zealand. J Neurol Neurosurg Psychiatry 88: 632–638.
  • Cabre P (2009) Environmental changes and epidemiology of multiple scle‑ rosis in the French West Indies. J Neurol Sci 286: 58–61.
  • Cabrera‑Gómez J, Kurtzke J, González‑Quevedo A, Lara‑Rodríguez R (2009) An epidemiological study of neuromyelitis optica in Cuba. J Neurol 256: 35–44.
  • Cai MT, Zhang YX, Zheng Y, Fang  W, Ding MP (2019) Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis op‑ tica spectrum disorder and acute disseminated encephalomyelitis. Mult Scler Relat Disord 32: 41–45.
  • Caruso R, Pallone F, Monteleone G (2007) Emerging role of IL‑23/IL‑17 axis in H pylori‑associated pathology. World J Gastroenterol 13: 5547–5551.
  • Carvalho D, Tironi T, Freitas D, Kleinpaul R, Talim N, Lana‑Peixoto M (2014) Sjögren syndrome and neuromyelitis optica spectrum disorder co‑exist in a common autoimmune milieu. Arq Neuropsiquiatr 72: 619–624.
  • Chambers E, Hawrylowicz C (2011) The impact of vitamin D on regulatory T cells. Curr Allergy Asthma Rep 11: 29–36.
  • Chan KH, Tse CT, Chung CP, Lee RL, Kwan JS, Ho PW, Ho JW (2011) Brain involvement in neuromyelitis optica spectrum disorders. Arch Neurol 68: 1432–1439.
  • Chang K, Ro L, Lyu R, Chen C (2015) Biomarkers for neuromyelitis optica. Clin Chim Acta 440: 64–71.
  • Chaplin (2010) Overview of the immune response. J Allergy Clin Immunol 125: S3–23.
  • Chen A, Fang Z, Chen X, Yang S, Zhou Y, Mao L, Xia Y, Jin H, Li Y, You M, Wang X, Lei H, He Q, Hu B (2019) Microglia‑derived TNF‑α mediates en‑ dothelial necroptosis aggravating blood brain‑barrier disruption after ischemic stroke. Cell Death Dis10: 487.
  • Cheng C, Jiang Y, Lu X, Gu F, Kang Z, Dai Y, Lu Z, Hu X (2016) The role of anti‑ aquaporin 4 antibody in the conversion of acute brainstem syndrome to neuromyelitis optica. BMC Neurol 16: 203.
  • Chitnis T, Ness J, Krupp  L, Waubant E, Hunt T, Olsen C, Rodriguez  M, Lotze T, Gorman M, Benson L, Belman A, Weinstock‑Guttman B, Aaen G, Graves J, Patterson M, Rose J, Casper T (2016) Clinical features of neuro‑ myelitis optica in children: US Network of Pediatric MS Centers report. Neurology 86: 245–252.
  • Cree B, Spencer C, Varrin‑Doyer M, Baranzini S, Zamvil S (2016) Gut micro‑ biome analysis in neuromyelitis optica reveals overabundance of Clos‑ tridium perfringens. Ann Neurol 80: 443–447
  • Cossburn  M, Tackley G, Baker K, Ingram G, Burtonwood  M, Malik G, Pickersgill T, te Water Naudé J, Robertson N (2012) The prevalence of neuromyelitis optica in South East Wales. Eur J Neurol 19: 655–659.
  • Costanzi C, Matiello M, Lucchinetti C, Weinshenker B, Pittock S, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine: tolerability, efficacy, and predic‑ tors of benefit in neuromyelitis optica. Neurology 77: 659–666.
  • da Fonseca A, Matias D, Garcia C, Amaral R, Geraldo L, Freitas C, Lima F (2014) The impact of microglial activation on blood‑brain barrier in brain diseases. Front Cell Neurosci 8: 362.
  • Deeb K, Eby J, Labault‑Santiago J (2019) Demyelinating syndrome in sys‑ temic sclerosis and neuromyelitis optica. BMC Neurol 19: 234.
  • D’Elios M, Amedei A, Cappon A, Del Prete G, de Bernard M (2007) The neu‑ trophil‑ activating protein of Helicobacter pylori (HP‑NAP) as an immune modulating agent. FEMS Immunol Med Microbiol 50: 157–164.
  • de Heer E, Ten Have M, van Marwijk H, Dekker J, de Graaf R, Beekman A, van der Feltz‑Cornelis C (2018) Pain as a risk factor for common men‑ tal disorders. Results from the Netherlands Mental Health Survey and Incidence Study‑2: a  longitudinal, population‑based study. Pain 159: 712–718.
  • de Seze J, Blanc F, Jeanjean L, Zéphir H, Labauge P, Bouyon M, Ballonzoli L, Castelnovo G, Fleury M, Defoort S, Vermersch P, Speeg C (2008) Optical coherence tomography in neuromyelitis optica. Arch Neurol 65: 920–923.
  • de Seze J (2013) Inflammatory optic neuritis: from multiple sclerosis to neuromyelitis optica. Neuroophthalmology 37: 141–145.
  • Deschamps R, Paturel L, Jeannin S, Chausson N, Olindo S, Béra O, Bellance R, Smadja D, Césaire D, Cabre P (2011) Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro‑Caribbean population. Mult Scler 17: 24–31.
  • Devic E (1894) Myélite subaiguë compliquée de névrite optique (in French). Bull Méd 8: 1033–1034.
  • Dutra B, da Rocha A, Nunes R, Maia ACM Júnior (2018) Neuromyelitis optica spectrum disorders: spectrum of mr imaging findings and their differen‑ tial diagnosis. Radiographics 38: 169–193. Duvernoy H, Risold PY (2007) The circumventricular organs: an atlas of comparative anatomy and vascularization. Brain Res Rev 56: 119–147.
  • Elsone L, Goh YY, Trafford R, Mutch K, Jacob A (2013) How often does re‑ spiratory failure occur in neuromyelitis optica? J Neurol Neurosurg Psy‑ chiatry 84: e2.
  • Eskandarieh, Nedjat S, Abdollahpour I, Azimi A, Moghadasi A, Asgari N, Sahraian  M (2018) Environmental risk factors in neuromyelitis optica spectrum disorder: a case‑ control study. Acta Neurol Belg 118: 277–287.
  • Fang W, Zheng Y, Yang F, Cai MT, Shen CH, Liu ZR, Zhang YX, Ding MP (2020) Short segment myelitis as the initial and only manifestation of aqua‑ porin‑4 immunoglobulin G‑positive neuromyelitis optica spectrum dis‑ orders. Ther Adv Neurol Disord 13: 1756286419898594.
  • Felix C, Levin M, Verkman A (2016) Complement‑independent retinal pa‑ thology produced by intravitreal injection of neuromyelitis optica immu‑ noglobulin G. J Neuroinflammation 13: 275. Flanagan E, Weinshenker B, Krecke K, Lennon V, Lucchinetti C, McKeon A, Wingerchuk D, Shuster E, Jiao Y, Horta E, Pittock S (2015) Short myelitis lesions in aquaporin‑4‑IgG‑positive neuromyelitis optica spectrum dis‑ orders. JAMA Neurol 72: 81–87.
  • Fragoso Y, Ruocco H, Dias R, Cabeça H, Gonçalves R, de Carvalho Sousa N, Spessotto C, Tauil C, Alves‑Leon S, Gomes S, Gonçalves M, Machado S, Anacleto A, Correa E, Pimentel M, Santos G (2019) Late onset of neuro‑ myelitis optica spectrum disorders. Neurol Ther 8: 477–482.
  • Fujihara K, Misu T, Nakashima I, Takahashi T, Bradl  M, Lassmann H, Takano R, Nishiyama S, Takai Y, Suzuki C, Sato D, Kuroda H, Nakamura M, Fujimori J, Narikawa K, Sato S, Itoyama Y, Aoki M (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3: 58–73.
  • Gelfand J, Cree B, Nolan R, Arnow S, Green A (2013) Microcystic inner nu‑ clear layer abnormalities and neuromyelitis optica. JAMA Neurol 70: 629–633.
  • Gleiser C, Wagner A, Fallier‑Becker P, Wolburg H, Hirt B, Mack A (2016) Aquaporin‑4 in astroglial cells in the CNS and supporting cells of sensory organs – a comparative perspective. Int J Mol Sci 17: 1411.
  • Gruber‑Schoffnegger D, Drdla‑Schutting R, Hönigsperger C, Wunder‑ baldinger G, Gassner  M, Sandkühler J (2013) Induction of thermal hyperalgesia and synaptic long‑ term potentiation in the spinal cord lamina I by TNF‑α and IL‑1β is mediated by glial cells. J Neurosci 33: 6540–6551. Hamid S, Whittam D, Mutch K, Linaker S, Solomon T, Das K, Bhojak  M, Jacob A (2017) What proportion of AQP4‑IgG‑negative NMO spectrum disorder patients are MOG‑IgG positive? A cross sectional study of 132 patients. J Neurol 264: 2088–2094.
  • Harada K, Fujita Y, Okuno T, Tanabe S, Koyama Y, Mochizuki H, Yamashita T (2018) Inhibition of RGMa alleviates symptoms in a rat model of neuro‑ myelitis optica. Sci Rep 8: 34.
  • Hayashida S, Masaki K, Yonekawa T, Suzuki S, Hiwatashi A, Matsushita T, Watanabe M, Yamasaki R, Suenaga T, Iwaki T, Murai H, Kira JI (2017) Early and extensive spinal white matter involvement in neuromyelitis optica. Brain Pathol 27: 249–265.
  • Herges K, de Jong B, Kolkowitz I, Dunn C, Mandelbaum G, Ko R, Maini A, Han M, Killestein J, Polman C, Goodyear A, Dunn J, Steinman L, Axtell R (2012) Protective effect of an elastase inhibitor in a neuromyelitis opti‑ ca‑like disease driven by a peptide of myelin oligodendroglial glycopro‑ tein. Mult Scler 18: 398–408.
  • Hinson R, Roemer S, Lucchinetti C, Fryer J, Kryzer T, Chamberlain J, Howe C, Pittock S, Lennon V (2008) Aquaporin‑4‑binding autoantibod‑ ies in patients with neuromyelitis optica impair glutamate transport by down‑regulating EAAT2. J Exp Med 205: 2473–2481.
  • Hokari  M, Yokoseki A, Arakawa  M, Saji E, Yanagawa K, Yanagimura  F, Toyoshima Y, Okamoto K, Ueki S, Hatase T, Ohashi R, Fukuchi T, Akazawa K, Yamada M, Kakita A, Takahashi H, Nishizawa M, Kawachi I (2012) Clinicopathological features in anterior visual pathway in neuro‑ myelitis optica. Ann Neurol 79: 605–624.
  • Houzen H, Kondo K, Niino M, Horiuchi K, Takahashi T, Nakashima I, Tanaka K (2017) Prevalence and clinical features of neuromyelitis optica spectrum disorders in northern Japan. Neurology 89: 1995–2001.
  • Hsu HC, Yang P, Wang J, Wu Q, Myers R, Chen J, Yi J, Guentert T, Tousson A, Stanus AL, Le TV, Lorenz G, Xu H, Kolls K, Carter H, Chaplin D, Williams W, Mountz D (2008) Interleukin 17‑producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoim‑ mune BXD2 mice. Nat Immunol 9: 166–175.
  • Huh SY, Kim SH, Hyun JW, Jeong IH, Park M, Lee SH4, Kim H (2017) Short segment myelitis as a first manifestation of neuromyelitis optica spec‑ trum disorders. Mult Scler 23: 413–419.
  • Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, Minohara M, Murai H, Mihara F, Taniwaki T, Kira J (2005) Intrathecal activation of the IL‑17/IL‑8 axis in opticospinal multiple sclerosis. Brain 128: 988–1002.
  • Jacob A, Panicker J, Lythgoe D, Elsone L, Mutch K, Wilson M, Das K, Boggild M (2013) The epidemiology of neuromyelitis optica amongst adults in the Merseyside county of United Kingdom. J Neurol 260: 2134–2137.
  • Jacob A, Matiello M, Weinshenker B, Wingerchuk D, Lucchinetti C, Shuster E, Carter J, Keegan B, Kantarci O, Pittock S (2009) Treatment of neuromy‑ elitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 66: 1128–1133.
  • Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical fea‑ tures, immunopathogenesis and treatment. Clin Exp Immunol 176: 149–164.
  • Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamaschi R, Rommer P, Kleiter I, Stich O, Reuss R, Rauer S, Zettl U, Wandinger K, Melms A, Aktas O, Kristoferitsch W, Wildemann B (2011) Cerebrospinal fluid findings in aquaporin‑4 antibody positive neuromyelitis optica: re‑ sults from 211 lumbar punctures. J Neurol Sci 306: 82–90.
  • Jayarangaiah A, Sehgal R, Epperla N (2014) Sjögren’s syndrome and neuro‑ myelitis optica spectrum disorders (NMOSD)‑a case report and review of literature. BMC Neurol 14: 200.
  • Jazini M, Roghanian R, Zarkesh Esfahani H, Shaygannejad V, Mirmosayyeb O (2019) Evaluation of the possible relation between neuromyelitis optica and mumps infection in Isfahan, Iran. RJMS 26: 50–58.
  • Jeong S, Lim YM, Jin JY, Kim H, Kim KK (2018) Neuromyelitis optica spec‑ trum disorder in a patient with ankylosing spondylitis. J Clin Neurol 14: 102–103.
  • Jiao Y, Fryer J, Lennon V, Jenkins S, Quek A, Smith C, McKeon A, Costanzi C, Iorio R, Weinshenker B, Wingerchuk D, Shuster E, Lucchinetti C, Pittock S (2013) Updated estimate of AQP4‑IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81: 1197–1204.
  • Jonsson D, Sveinsson O, Hakim R, Brundin  L (2019) Epidemiology of NMOSD in Sweden from 1987 to 2013 – A nationwide population‑based study. Neurology 93: e181‑e189.
  • Kanbayashi T, Shimohata T, Nakashima I, Yaguchi H, Yabe I, Nishizawa M, Shimizu T, Nishino S (2009) Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and im‑ munological implications. Arch Neurol 66: 1563–1566.
  • Kaneko K, Sato D, Nakashima I, Nishiyama S, Tanaka S, Marignier R, Hyun J, Oliveira  L, Reindl  M, Seifert‑Held T, Sepulveda  M, Siritho S, Waters P, Kurosawa K, Akaishi T, Kuroda H, Misu T, Prayoonwiwat N, Berger T, Saiz  A, Kim H, Nomura K, Callegaro D, Fujihara K, Aoki  M (2016) My‑ elin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 87: 1257–1259.
  • Kallollimath P, Gujjar A, Patil M (2018) Symptomatic narcolepsy as a pre‑ senting feature of neuromyelitis optica. Ann Indian Acad Neurol 21: 156–158.
  • Kaufhold F, Zimmermann H, Schneider E, Ruprecht K, Paul F, Oberwahren‑ brock T, Brandt A (2013) Optic neuritis is associated with inner nuclear layer thickening and microcystic macular edema independently of mul‑ tiple sclerosis. PLoS One 8: e71145.
  • Kay C, Scola R, Lorenzoni P, Jarius S, Arruda W, Werneck L (2008) NMO‑IgG positive neuromyelitis optica in a patient with myasthenia gravis but no thymectomy. J Neurol Sci 275: 148–150.
  • Khanna S, Sharma A, Huecker J, Gordon  M, Naismith R, Van Stavern G (2012) Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 32: 216–220.
  • Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, Misu T, Fujihara K, Kim HJ (2010) Characteristic brain magnetic resonance imaging abnor‑ malities in central nervous system aquaporin‑4 autoimmunity. Mult Scler 16: 1229–1236.
  • Kim H, Paul F, Lana‑Peixoto M, Tenembaum S, Asgari N, Palace J, Klawiter E, Sato D, de Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH (2015) MRI characteristics of neuromyelitis optica spectrum dis‑ order: an international update. Neurology 84: 1165–1173.
  • Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz‑Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han  M, Leite MI, Palace J, Kim HJ (2018) Racial dif‑ ferences in neuromyelitis optica spectrum disorder. Neurology 91: e2089‑e2099. Kim W, Kim SH, Huh SY, Kim HJ (2012) Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012: 735486.
  • Kim W, Lee JE, Kim SH, Huh SY, Hyun JW, Jeong IH, Park MS, Cho JY, Lee SH, Lee KS, Kim HJ (2016) Cerebral cortex involvement in neuromyelitis opti‑ ca spectrum disorder. J Clin Neurol 12: 188–193.
  • Kim SH, Kim W, Park M, Sohn E, Li X, Kim H (2010) Efficacy and safety of mi‑ toxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol 68: 473–479.
  • Kim SH, Huh SY, Lee S, Joung A, Kim H (2013) A 5‑year follow‑up of ritux‑ imab treatment in patients with neuromyelitis optica spectrum disor‑ der. JAMA Neurol 70: 1110–1117.
  • Kira J, Isobe N (2019) Helicobacter pylori infection and demyelinating dis‑ ease of the central nervous system. J Neuroimmunol 29: 14–19.
  • Kitic  M, Hochmeister S, Wimmer I, Bauer J, Misu T, Mader S, Reindl  M, Fujihara K, Lassmann H, Bradl M (2013) Intrastriatal injection of interleu‑ kin‑1 beta triggers the formation of neuromyelitis optica‑like lesions in NMO‑IgG seropositive rats. Acta Neuropathol Commun 1: 5. Kitley J, Elsone  L, George J, Waters P, Woodhall  M, Vincent A, Jacob A, Leite M, Palace J (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin‑4 antibodies. J Neurol Neurosurg Psychiatry 84: 918–921.
  • Kiu R, Hall L (2018) An update on the human and animal enteric pathogen Clostridium perfringens. Emerg Microbes Infect 7: 141.
  • Koga  M, Takahashi T, Kawai  M, Fujihara K, Kanda T (2011) A serological analysis of viral and bacterial infections associated with neuromyelitis optica. J Neurol Sci 300: 19–22.
  • Kouro T, Takatsu K (2009) IL‑5‑ and eosinophil‑mediated inflammation: from discovery to therapy. Int Immunol 21: 1303–1309.
  • Kowarik C, Soltys J, Bennett L (2014) The treatment of neuromyelitis optica. J Neuroophthalmol 34: 70–82.
  • Kremer L, Mealy M, Jacob A, Nakashima I, Cabre P, Bigi S, Paul F, Jarius S, Aktas O, Elsone L, Mutch K, Levy M, Takai Y, Collongues N, Banwell B, Fujihara K, de Seze J (2014) Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients. Mult Scler 20: 843–847.
  • Lachmann P, Hugh‑Jones NC (1984) Initiation of complement activation. Springer Semin Immuno Pathol 7: 143–162.
  • Lana‑Peixoto  M, Callegaro D (2012) The expanded spectrum of neuro‑ myelitis optica: evidences for a new definition. Arq Neuropsiquiatr 70: 807–13.
  • Lana‑Peixoto  M, Talim N (2019) Neuromyelitis optica spectrum disorder (NMOSD) and anti-MOG syndromes. Biomedicines 7: pii: E42. Lee J, Lim M, Kim Y, Lee J, Kim H, Jin Y, Oh J, Kim K (2019) The clinical and prognostic value of antinuclear antibodies in NMO‑IgG seropositive neuromyelitis optica spectrum disorder. J Neuroimmunol 328: 1–4.
  • Leite  M, Coutinho E, Lana‑Peixoto  M, Apostolos S, Waters P, Sato D, Melamud L, Marta M, Graham A, Spillane J, Villa A, Callegaro D, Santos E, da Silva A, Jarius S, Howard R, Nakashima I, Giovannoni G, Buckley C, Hilton‑Jones D, Vincent A, Palace J (2012) Myasthenia gravis and neuro‑ myelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78: 1601–1607.
  • Lennon  V, Wingerchuk D, Kryzer T, Pittock S, Lucchinetti C, Fujihara K, Nakashima I, Weinshenker B (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106–2112.
  • Lennon V, Kryzer T, Pittock S, Verkman A, Hinson S (2005) IgG marker of optic‑spinal multiple sclerosis binds to the aquaporin‑4 water channel. J Exp Med 202: 473–477.
  • Levy M, Wildemann B, Jarius S, Orellano B, Sasidharan S, Weber M, Stuve O (2014) Immunopathogenesis of neuromyelitis optica. Adv Immunol 121: 213–242.
  • Li W, Minohara M, Piao H, Matsushita T, Masaki K, Matsuoka T (2009) Asso‑ ciation of anti‑Helicobacter pylori neutrophil‑activating protein antibody response with anti‑ aquaporin‑4 autoimmunity in Japanese patients with multiple sclerosis and neuromyelitis optica. Mult Scler 15: 1411–1421.
  • Li Y, Xie P, Lv F, Mu J, Li Q, Yang Q, Hu M, Tang H, Yi J (2008) Brain magnetic resonance imaging abnormalities in neuromyelitis optica. Acta Neurol Scand 118: 218–225.
  • Linhares U, Schiavoni P, Barros P, Kasahara T, Teixeira B, Ferreira T, Alvarenga R, Hygino J, Vieira M, Bittencourt V, Andrade R, Andrade A, Bento C (2013) The ex vivo production of IL‑6 and IL‑21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients. J Clin Immunol 33: 179–189.
  • Lisi S, Sisto M, Lofrumento D, D’Amore M (2012) Sjogren’s syndrome auto‑ antibodies provoke changes in gene expression profiles of inflammato‑ ry cytokines triggering a pathway involving TACE/NF‑κB. Lab Invest 92: 615–624.
  • Liu Y, Given K, Harlow D, Matschulat A, Macklin  W, Bennett J, Owens G (2017) Myelin‑specific multiple sclerosis antibodies cause comple‑ ment‑dependent oligodendrocyte loss and demyelination. Acta Neuro‑ pathol Commun 5: 25.
  • Liu Y, Given K, Owens G, Macklin W, Bennett J (2018) Distinct patterns of glia repair and remyelination in antibody‑mediated demyelination mod‑ els of multiple sclerosis and neuromyelitis optica. Glia 66: 2575–2588.
  • Lloyd A, Davies C, Miron V (2017) Microglia: origins, homeostasis, and roles in myelin repair. Curr Opin Neurobiol 47: 113–120.
  • López‑Chiriboga A, Flanagan E (2018) Diagnostic and therapeutic approach to autoimmune neurologic disorders. Semin Neurol 38: 392–402.
  • Long Y, Gao C, Qiu W, Hu X, Shu Y, Peng F, Lu Z (2013) Helicobacter pylori infection in neuromyelitis optica and multiple sclerosis. Neuroimmuno‑ modulation 20: 107–112.
  • Lucchinetti C, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff R, Trebst C, Weinshenker B, Wingerchuk D, Parisi J, Lassmann H (2002) A role for humoral mechanisms in the pathogenesis of Devic’s neuro‑ myelitis optica. Brain 125: 1450–1461.
  • Lucchinetti C, Guo Y, Popescu F, Fujihara K, Itoyama Y, Misu T (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24: 83–97.
  • Mao YM, Zhao CN, Leng J, Leng RX, Ye DQ, Zheng SG, Pan HF (2019) In‑ terleukin‑ 13: A promising therapeutic target for autoimmune disease. Cytokine Growth Factor Rev 45: 9–23.
  • Marignier R, Nicolle A, Watrin C, Touret  M, Cavagna S, Varrin‑Doyer  M, Cavillon G, Rogemond V, Confavreux C, Honnorat J, Giraudon P (2010) Oligodendrocytes are damaged by neuromyelitis optica immunoglobu‑ lin G via astrocyte injury. Brain133: 2578–2591.
  • Marignier R, Bernard‑Valnet R, Giraudon P, Collongues N, Papeix C, Zéphir  H, Cavillon G, Rogemond  V, Casey R, Frangoulis B, De Sèze J, Vukusic S, Honnorat J, Confavreux C (2013) Aquaporin‑4 antibody‑neg‑ ative neuromyelitis optica: distinct assay sensitivity‑dependent entity. Neurology 80: 2194–2200.
  • Masuda H, Mori M, Uzawa A, Muto M, Uchida T, Kuwabara S (2016) Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. Eur J Neurol 23: 276–281.
  • Matiello M, Schaefer‑Klein J, Sun D, Weinshenker B (2013) Aquaporin 4 ex‑ pression and tissue susceptibility to neuromyelitis optica. JAMA Neurol 70: 1118–1125.
  • McKeon A, Lennon V, Jacob A, Matiello M, Lucchinetti C, Kale N, Chan K, Weinshenker B, Apiwattinakul M, Wingerchuk D, Pittock S (2009) Coexis‑ tence of myasthenia gravis and serological marker of neurological auto‑ immunity in neuromyelitis optica. Muscle Nerve 39: 87–90.
  • Mealy M, Whetstone A, Orman G, Izbudak I, Calabresi P, Levy M (2015) Longitudinally extensive optic neuritis as an MRI biomarker distin‑ guishes neuromyelitis optica from multiple sclerosis. J Neurol Sci 355: 59–63.
  • Mehta L, Samuelsson M, Kleiner A, Goodman A, Anolik J, Looney R, Schwid S (2008) Neuromyelitis optica spectrum disorder in a patient with system‑ ic lupus erythematosus and anti‑phospholipid antibody syndrome. Mult Scler 14: 425–427.
  • Melamed E, Levy  M, Waters J, Sato K, Bennett  L, John R, Hooper C, Saiz A, Bar‑Or A, Kim J, Pandit L, Leite I, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith J, Yeaman R, Han H, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana‑Peixoto  M, Nakashima, O’Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan P, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S (2015) Update on bio‑ markers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2: e134.
  • Meng X, Zhang Y, Lao L, Saito R, Li A, Bäckman C, Berman B, Ren K, Wei PK, Zhang RX (2013) Spinal interleukin‑17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model. Pain 154: 294–305.
  • Merle H, Olindo S, Bonnan M, Donnio A, Richer R, Smadja D, Cabre P (2007) Natural history of the visual impairment of relapsing neuromyelitis opti‑ ca. Ophthalmology 114: 810–815.
  • Merle H, Olindo S, Jeannin S, Hage R, Donnio A, Richer R, Cabre P (2013) Visual field characteristics in neuromyelitis optica in absence of and af‑ ter one episode of optic neuritis. Clin Ophthalmol 7: 1145–1153. Meriggioli M, Sanders D (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8: 475–490. Min JH, Waters P, Vincent A Cho HJ, Joo BE, Woo SY, Lee SY, Shin HY, Lee KH, Kim B (2014) Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability. PLoS One 9: e107274. Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y (2005) Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurol‑ ogy 65: 1479–1482. Misu T, Fujihara K, Nakamura M, Murakami K, Endo M, Konno H, Itoyama Y (2006) Loss of aquaporin‑4 in active perivascular lesions in neuromyeli‑ tis optica: a case report. Tohoku J Exp Med 209: 269–275. Misu T, Höftberger R, Fujihara K, Wimmer I, Takai Y, Nishiyama S, Nakashima  I, Konno H, Bradl  M, Garzuly F, Itoyama Y, Aoki  M, Lassmann H (2013) Presence of six different lesion types suggests di‑ verse mechanisms of tissue injury in neuromyelitis optica. Acta Neuro‑ pathol 125: 815–827.
  • Mitsdoerffer  M, Kuchroo  V, Korn T (2013) Immunology of neuromyelitis optica: A T Cell‑B cell collaboration. Ann N Y Acad Sci 1283: 57–66.
  • Miyazawa I, Fujihara K, Itoyama Y (2002) Eugène Devic (1858–1930). J Neu‑ rol 249: 351–352.
  • Mori M, Hosoya M, Hiwasa T, Hayakawa S, Uzawa A, Kuwabara S (2011) Detection of mumps virus RNA in cerebrospinal fluid of patients with neuromyelitis optica. Neurol Sci 32: 795–7999.
  • Nagelhus E, Ottersen O (2013) Physiological Roles of Aquaporin‑4 in Brain. Physiol Rev 93: 1543–1562.
  • Nakajima H, Hosokawa T, Sugino  M, Kimura F, Sugasawa J, Hanafusa T, Takahashi T (2010) Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol 10: 45. Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, Takahashi T, Itoyama Y (2008) Preferential spinal central gray matter in‑ volvement in neuromyelitis optica. An MRI study. J Neurol 255: 163–170.
  • Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, Watanabe S, Itoyama Y (2009) Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler 15: 695–700.
  • Neely J, Christensen B, Nielsen S, Agre P (1999) Heterotetrameric compo‑ sition of aquaporin‑4 water channels. Biochemistry 38: 11156–11163.
  • Nelson A, Khodadoust  M, Prodhomme T, Spencer C, Patarroyo C, Varrin‑Doyer M, Ho D, Stroud M, Zamvil S (2010) Immunodominant T cell determinants of aquaporin‑4, the autoantigen associated with neu‑ romyelitis optica. PLoS One 5: e15050.
  • Netravathi M, Saini J, Mahadevan A, Hari‑Krishna B, Yadav R, Pal P, Satish‑ chandra P (2017) Is pruritus an indicator of aquaporin‑positive neuro‑ myelitis optica? Mult Scler 23: 810–817.
  • Nicchia G, Cogotzi  L, Rossi A, Basco D, Brancaccio A, Svelto  M, Frigeri A (2008) Expression of multiple AQP4 pools in the plasma membrane and their association with the dystrophin complex. J Neurochem 105: 2156–2165. Nicholson (2016) The immune system. Essays Biochem 60: 275–301.
  • Oertel F, Schließeit J, Brandt A, Paul F (2019) Cognitive impairment in neu‑ romyelitis optica spectrum disorders: a review of clinical and neurora‑ diological features. Front Neurol 10: 608.
  • Oh J, Levy M (2012) Neuromyelitis optica: an antibody‑mediated disorder of the central nervous system. Neurol Res Int 2012: 460825.
  • Pandit L (2015) Neuromyelitis optica spectrum disorders: An update. Ann Indian Acad Neurol 18: S11–15.
  • Papais‑Alvarenga R, Carellos S, Alvarenga  M, Holander C, Bichara R, Thuler L (2008) Clinical course of optic neuritis in patients with relapsing neuromyelitis optica. Arch Ophthalmol 126: 12–16.
  • Papp V, Illes Z, Magyari M, Koch‑Henriksen N, Kant M, Pfleger C, Roemer S, Jensen M, Petersen A, Nielsen H, Rosendahl L, Mezei Z, Christensen T, Svendsen K, Hyldgaard Jensen P, Lydolph M, Heegaard N, Frederiksen J, Sellebjerg F, Stenager E, Petersen T (2018) Nationwide prevalence and incidence study of neuromyelitis optica spectrum disorder in Denmark. Neurology 91: e2265‑e2275.
  • Parratt J, Prineas J (2010) Neuromyelitis optica: a  demyelinating disease characterized by acute destruction and regeneration of perivascular as‑ trocytes. Mult Scler 16: 1156–1172.
  • Pekcevik Y, Mitchell CH, Mealy MA, Orman G, Lee I, Newsome S, Thompson C, Pardo C, Calabresi P, Levy M, Izbudak I (2016) Differentiating neuromyeli‑ tis optica from other causes of longitudinally extensive transverse myeli‑ tis on spinal magnetic resonance imaging. Mult Scler 22: 302–311.
  • Persson T, Monsef N, Andersson P, Bjartell A, Malm J, Calafat J, Egesten A (2003) Expression of the neutrophil‑activating CXC chemokine ENA‑78/ CXCL5 by human eosinophils. Clin Exp Allergy 33: 531–537.
  • Pittock S, Weinshenker B, Lucchinetti C, Wingerchuk D, Corboy J, Lennon V (2006) Neuromyelitis optica brain lesions localized at sites of high aqua‑ porin 4 expression. Arch Neurol 63: 964–968.
  • Pittock S, Lennon V, de Seze J, Vermersch P, Homburger H, Wingerchuk D, Lucchinetti C, Zéphir H, Moder K, Weinshenker B (2008) Neuromyelitis optica and non organ‑ specific autoimmunity Arch Neurol 65: 78–83.
  • Pittock S, Lucchinetti C (2016) Neuromyelitis optica and the evolving spec‑ trum of autoimmune aquaporin‑4 channelopathies: a decade later. Ann N Y Acad Sci 1366: 20–39.
  • Pittock S, Lennon V, McKeon A, Mandrekar J, Weinshenker B, Lucchinetti C, O’Toole O, Wingerchuk D (2013) Eculizumab in AQP4‑IgG‑positive re‑ lapsing neuromyelitis optica spectrum disorders: an open‑label pilot study. Lancet Neurol 12: 554–562.
  • Popescu B, Parisi J, Cabrera‑Gómez J, Newell K, Mandler R, Pittock S, Lennon V, Weinshenker B, Lucchinetti C (2010) Absence of cortical de‑ myelination in neuromyelitis optica. Neurology 75: 2103–2109.
  • Popescu B, Lennon  V, Parisi J, Howe C, Weigand S, Cabrera‑Gómez J, Newell K, Mandler R, Pittock S, Weinshenker B, Lucchinetti C (2011) Neu‑ romyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76: 1229–1237.
  • Qian P, Lancia S, Alvarez E, Klawiter E, Cross A, Naismith R (2012) Asso‑ ciation of neuromyelitis optica with severe and intractable pain. Arch Neurol 69: 1482–1487.
  • Quek A, McKeon A, Lennon  V, Mandrekar J, Iorio R, Jiao Y, Costanzi C, Weinshenker B, Wingerchuk D, Lucchinetti C, Shuster E, Pittock S (2012) Effects of age and sex on aquaporin‑4 autoimmunity. Arch Neurol 69: 1039–1043.
  • Radbruch A, Muehlinghaus G, Luger O, Inamine A, Smith G, Dörner T, Hiepe F (2006) Competence and competition: the challenge of becoming a long‑lived plasma cell. Nat Rev Immunol 6: 741–750.
  • Ransohoff R, Khoury J (2015) Microglia in Health and Disease. Cold Spring Harb Perspect Biol 8: a020560. Ratelade J, Verkman A (2012) Neuromyelitis optica: Aquaporin‑4 based pathogenesis mechanisms and new therapies. Int J Biochem Cell Biol 44: 1519–1530.
  • Revitt‑Mills S, Rood J, Adams V (2015) Clostridium perfringens extracellular toxins and enzymes: 20 and counting. Microbiol Austral 36: 114–117.
  • Ricklin D, Hajishengallis G, Yang K, Lambris J (2010) Complement: a  key system for immune surveillance and homeostasis. Nat Immunol 11: 785–797.
  • Roemer S, Parisi J, Lennon  V, Benarroch E, Lassmann H, Bruck  W, Mandler R, Weinshenker B, Pittock S, Wingerchuk D, Lucchinetti C (2007) Pattern‑specific loss of aquaporin‑4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194–1205. Rosenblum M, Remedios K, Abbas A (2015) Mechanisms of human autoim‑ munity. J Clin Invest 125: 2228–2233.
  • Rubin D, Batra A, Vaitkevicius H, Vodopivec I (2018) Autoimmune neurolog‑ ic disorders. Am J Med 131: 226–236.
  • Saini H, Fernandez G, Kerr D, Levy  M (2010) Differential expression of aquaporin‑4 isoforms localizes with neuromyelitis optica disease activi‑ ty. J Neuroimmunol 221: 68–72.
  • Saji E, Arakawa M, Yanagawa K, Toyoshima Y, Yokoseki A, Okamoto K, Ot‑ suki M, Akazawa K, Kakita A, Takahashi H, Nishizawa M, Kawachi I (2013) Cognitive impairment and cortical degeneration in neuromyelitis optica. Ann Neurol 73: 65–76.
  • Sato D, Callegaro D, Lana‑Peixoto  M, Waters P, de Haidar Jorge F, Takahashi T, Nakashima I, Apostolos‑Pereira S, Talim N, Simm R, Lino A, Misu T, Leite M, Aoki M, Fujihara K (2014) Distinction between MOG an‑ tibody‑positive and AQP4 antibody‑positive NMO spectrum disorders. Neurology 82: 474–481.
  • Sawaya R, Radwan W (2013) Sarcoidosis associated with neuromyelitis op‑ tica. J Clin Neurosci 20: 1156–1158.
  • Schattling B, Engler J, Volkmann C, Rothammer N, Woo  M, Petersen  M, Winkler I, Kaufmann  M, Rosenkranz S, Fejtova A, Thomas U, Bose  A, Bauer  S, Träger S, Miller K, Brück  W, Duncan K, Salinas G, Soba P, Gundelfinger E, Merkler D, Friese M (2019) Bassoon proteinopathy drives neurodegeneration in multiple sclerosis. Nat Neurosci 22: 887–896.
  • Scharfman H, MacLusky N (2008) Estrogen‑growth factor interactions and their contributions to neurological disorders. Headache 48 : S77–89.
  • Schousboe A, Sarup A, Bak L, Waagepetersen H, Larsson O (2004) Role of astrocytic transport processes in glutamatergic and GABAergic neuro‑ transmission. Neurochem Int 45: 521–517.
  • Segal  W (2005) How neutrophils kill microbes. Annu Rev Immunol 23: 197–223.
  • Sepúlveda M, Aldea M, Escudero D, Llufriu S, Arrambide G, Otero‑Romero S, Sastre‑ Garriga J, Romero‑Pinel  L, Martínez‑Yélamos S, Sola‑Valls  N, Armangué T, Sotoca J, Escartín A, Robles‑Cedeño R, Ramió‑Torrentà L, Presas‑Rodríguez S, Ramo‑Tello C, Munteis E, Pelayo R, Gubieras  L, Brieva  L, Ortiz N, Hervás  M, Mañé‑Martínez MA, Cano A, Vela E, Tintoré M, Blanco Y, Montalban X, Graus F, Saiz A (2017) Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. Mult Scler 1: 1352458517735191.
  • Serhan C, Savill J (2005) Resolution of inflammation: the beginning pro‑ grams the end. Nat Immunol 6): 1191–1197.
  • Serhan C (2007) Resolution phases of inflammation: novel endogenous anti‑ inflammatory and pro‑resolving lipid mediators and pathways. Annu Rev Immunol 25: 101–137.
  • Shen T, You Y, Arunachalam S, Fontes A, Liu S, Gupta V, Parratt J, Wang C, Barnett M, Barton J, Chitranshi N, Zhu L, Fraser C, Graham S, Klistorner A, Yiannikas C (2019) Differing structural and functional patterns of optic nerve damage in multiple sclerosis and neuromyelitis optica spectrum disorder. Ophthalmology 126: 445–453.
  • Shigemoto‑Mogami Y, Hoshikawa K, Sato K (2018) Activated Microglia Dis‑ rupt the Blood‑Brain Barrier and Induce Chemokines and Cytokines in a Rat in vitro Model. Front Cell Neurosci 12: 494.
  • Shosha E, Dubey D, Palace J, Nakashima I, Jacob A, Fujihara K, Takahashi T, Whittam D, Leite MI, Misu T, Yoshiki T, Messina S, Elsone L, Majed M, Flanagan E, Gadoth A, Huebert C, Sagen J, Greenberg B, Levy  M, Banerjee A, Weinshenker B, Pittock S (2018) Area postrema syndrome: Frequency, criteria, and severity in AQP4‑IgG‑positive NMOSD. Neurol‑ ogy 91: e1642‑e1651.
  • Soltys J, Liu Y, Ritchie A, Wemlinger S, Schaller K, Schumann H, Owens G, Bennett J (2019) Membrane assembly of aquaporin‑4 autoantibodies regulates classical complement activation in neuromyelitis optica. J Clin Invest 129: 2000–2013.
  • Sotirchos E, Saidha S, Byraiah G, Mealy M, Ibrahim M, Sepah Y, Newsome S, Ratchford J, Frohman E, Balcer  L, Crainiceanu C, Nguyen Q, Levy  M, Calabresi P (2013) In vivo identification of morphologic retinal abnor‑ malities in neuromyelitis optica. Neurology 80: 1406–1414.
  • Sun H, Sun X, Huang D, Wu L, Yu S (2019) Cerebral cortex impairment in neuromyelitis optica spectrum disorder: A case report and literature re‑ view. Mult Scler Relat Disord 32: 9–12.
  • Tahani, Dehghani  L, Jahanbani‑Ardakani H, Shaygannejad  V, Fazli A, Hamidavi A, Eskandari N (2019) Elevated serum level of IL‑4 in neuro‑ myelitis optica and multiple sclerosis patients. J Immunoassay Immu‑ nochem 40: 555–563.
  • Takano R, Misu T, Takahashi T, Izumiyama M, Fujihara K, Itoyama Y (2008) A prominent elevation of glial fibrillary acidic protein in the cerebrospi‑ nal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med 215: 55–59.
  • Takata K, Matsuzaki T, Tajika Y (2004) Aquaporins: water channel proteins of the cell membrane. Prog Histochem Cytochem 39: 1–83.
  • Thurgur H, Pinteaux E (2019) Microglia in the neurovascular unit: blood‑brain barrier‑microglia interactions after central nervous system disorders. Neuroscience 405: 55–67.
  • Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T; Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261: 1–16.
  • Unal A, Emre U, Atasoy H, Sumer M, Mahmutyazicioglu K (2005) Encepha‑ lomyelitis following mumps. Spinal Cord 43: 441–444.
  • Uzawa A, Mori  M, Iwai Y, Kobayashi  M, Hayakawa S, Kawaguchi N, Kuwabara S (2009) Association of anti‑aquaporin‑4 neuromyelitis opti‑ ca. Arch Neurol 67: 1201–1208.
  • Uzawa A, Mori M, Sawai S, Masuda S, Muto M, Uchida T, Ito S, Nomura F, Kuwabara S (2013) Cerebrospinal fluid interleukin‑6 and glial fibrillary acidic protein levels are increased during initial neuromyelitis optica at‑ tacks. Clin Chim Acta 421: 181–183.
  • Vaknin‑Dembinsky A, Brill  L, Kassis I, Petrou P, Ovadia H, Ben‑Hur T, Abramsky O, Karussis D (2016) T‑cell responses to distinct AQP4 pep‑ tides in patients with neuromyelitis optica (NMO). Mult Scler Relat Dis‑ ord 6: 28–36.
  • Vaknin‑Dembinsky A, Charbit H, Brill  L, Abramsky O, Gur‑Wahnon D, Ben‑Dov I, Lavon I (2016) Circulating microRNAs as biomarkers for rit‑ uximab therapy, in neuromyelitis optica (NMO). J  Neuroinflammation 13: 179.
  • Varrin‑Doyer  M, Spencer  M, Schulze‑Topphoff U, Nelson A, Stroud  M, Cree A, Zamvil S (2012) Aquaporin 4‑specific T cells in neuromyelitis op‑ tica exhibit a Th17 bias and recognize clostridium ABC transporter. Ann Neurol 72: 53–64.
  • Ventura R, Kister I, Chung S, Babb J, Shepherd T (2016) Cervical spinal cord atrophy in NMOSD without a history of myelitis or MRI‑visible lesions. Neurol Neuroimmunol Neuroinflamm 3: e224.
  • Wake H, Fields R (2011) Physiological function of microglia. Neuron Glia Biol 7: 1–3.
  • Wang F, Liu Y, Duan Y, Li K (2011) Brain MRI abnormalities in neuromyelitis optica. Eur J Radiol 80: 445–449.
  • Wang H, Dai Y, Qiu W, Lu Z, Peng F, Wang Y, Bao J, Li Y, Hu X (2011) Inter‑ leukin‑ 17‑secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J Clin Neurosci 18: 1313–1317.
  • Wang H, Zhong X, Wang K, Qiu W, Li J, Dai Y, Hu X (2012) Interleukin 17 gene polymorphism is associated with anti‑aquaporin 4 antibody‑posi‑ tive neuromyelitis optica in the Southern Han Chinese – A case control study. J Neurol Sci 314: 26–28.
  • Wang  L, Wang FS, Gershwin  M (2015) Human autoimmune diseases: a comprehensive update. J Intern Med 278: 369–395.
  • Waters P, Jarius S, Littleton E, Leite M, Jacob S, Gray B, Geraldes R, Vale T, Jacob A, Palace J, Maxwell S, Beeson D, Vincent A (2008) Aquaporin‑4 an‑ tibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65: 913–919.
  • Waters P, McKeon A, Leite  M, Rajasekharan S, Lennon  V, Villalobos A, Palace J, Mandrekar J, Vincent A, Bar‑Or A, Pittock S (2012) Serologic di‑ agnosis of NMO: a multicenter comparison of aquaporin‑4‑IgG assays. Neurology 78: 665–671.
  • Wei Q, Yanyu C, Rui L, Caixia L, Youming L, Jianhua H, Weihua M, Xiaobo S, Wen X, Ying C, Zhengqi L, Xueqiang H (2014) Human aquaporin 4 gene polymorphisms in Chinese patients with neuromyelitis optica. J Neuro‑ immunol 274: 192–196.
  • Wei XH, Na XD, Liao GJ, Chen QY, Cui Y, Chen FY, Li YY, Zang Y, Liu XG (2013) The up‑regulation of IL‑6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection. Exp Neurol 241: 159–168.
  • Wilson R, Makuch M, Kienzler K, Varley J, Taylor J, Woodhall M, Palace J, Leite I, Waters P, Irani R (2018) Condition‑dependent generation of aquaporin‑4 antibodies from circulating B cells in neuromyelitis optica. Brain 141: 1063–1074.
  • Wingerchuk D, Hogancamp W, O’Brien P, Weinshenker B (1999) The clin‑ ical course of neuromyelitis optica (Devic’s syndrome). Neurology 53: 1107–1114.
  • Wingerchuk D, Weinshenker B (2003) Neuromyelitis optica: clinical predic‑ tors of a relapsing course and survival. Neurology 60: 848–853.
  • Wingerchuk D, Weinshenker B (2012) The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 18: 5–10.
  • Wingerchuk D, Lennon V, Lucchinetti C, Pittock S, Weinshenker B (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6: 805–815.
  • Wingerchuk D, Banwell B, Bennett J, Cabre P, Carroll  W, Chitnis T, de Seze  J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana‑Peixoto  M, Levy  M, Simon  JH, Tenembaum S, Traboulsee A, Waters P, Wellik K, Weinshenker B (2015) International Panel for NMO Diagnosis. Interna‑ tional consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85: 177–189.
  • Wojkowska D, Szpakowski P, Ksiazek‑Winiarek D, Leszczynski M, Glabinski A (2014) Interactions between neutrophils, Th17 cells, and chemokines during the initiation of experimental model of multiple sclerosis. Media‑ tors Inflamm 2014: 590409.
  • Wu A, Zhong X, Wang H, Xu W, Cheng C, Dai Y, Bao J, Qiu W, Lu Z, Hu X (2012) Cerebrospinal fluid IL‑21 levels in neuromyelitis optica and multi‑ ple sclerosis. Can J Neurol Sci 39: 813–820.
  • Yang T, Wang S, Zheng Q, Wang L, Li Q, Wei M, Du Z, Fan Y (2016) Increased plasma levels of epithelial neutrophil‑activating peptide 78/CXCL5 during the remission of neuromyelitis optica. BMC Neurol 16: 96. Yonezu T, Ito S, Mori M, Ogawa Y, Makino T, Uzawa A, Kuwabara S (2014) “Bright spotty lesions” on spinal magnetic resonance imaging differ‑ entiate neuromyelitis optica from multiple sclerosis. Mult Scler 20: 331–337.
  • Zaidi SF (2016) Helicobacter pylori associated Asian enigma: Does diet de‑ serve distinction? World J Gastrointest Oncol 8: 341–350
  • Zalewski N, Morris P, Weinshenker B, Lucchinetti C, Guo Y, Pittock S, Krecke  K, Kaufmann T, Wingerchuk D, Kumar N, Flanagan E (2017) Ring‑enhancing spinal cord lesions in neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 88: 218–225.
  • Zephir H, Fajardy I, Outteryck O, Blanc F, Roger N, Fleury  M, Rudolf G, Marignier R, Vukusic S, Confavreux C, Vermersch P, de Seze J (2009) Is neuromyelitis optica associated with human leukocyte antigen? Mult Scler 15: 571–579.
  • Zeka B, Hastermann  M, Kaufmann N, Schanda K, Pende  M, Misu T, Rommer  P, Fujihara K, Nakashima I, Dahle C, Leutmezer F, Reindl  M, Lassmann H, Bradl M (2016) Aquaporin 4‑specific T cells and NMO‑IgG cause primary retinal damage in experimental NMO/SD. Acta Neuro‑ pathol Commun 4: 82.
  • Zeka B, Lassmann H, Bradl M (2017) Müller cells and retinal axons can be primary targets in experimental neuromyelitis optica spectrum disor‑ der. Clin Exp Neuroimmunol 8: 3–7.
  • Zhang J, An J (2007) Cytokines, inflammation, and pain. Int Anesthesiol Clin 45: 27–37.
  • Zhang H, Bennett J, Verkman A (2011) Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms. Ann Neurol 70: 943–954.
Typ dokumentu
Bibliografia
Identyfikatory
DOI
10.21307/ane‑2020‑023
Identyfikator YADDA
bwmeta1.element.agro-540d28b8-e595-4b32-b5b2-d52548290125
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.